From Wikipedia, the free encyclopedia - View original article
Dextromethorphan (DXM), a common active ingredient found in many over-the-counter cough suppressant cold medicines, is used as a recreational drug for its dissociative effects. It has almost no psychoactive effects at medically-recommended doses. Dextromethorphan has powerful dissociative properties when administered in doses well above those considered therapeutic for cough suppression. Recreational use of DXM is sometimes referred to in slang form as robo-tripping, whose prefix derives from the Robitussin brand name, or Triple Cs, which derives from the Coricidin brand (the pills were printed with "CCC").
In over the counter formulations, DXM is often combined with acetaminophen to relieve pain and to prevent recreational use; however, to achieve DXM's dissociative effects, the maximum daily therapeutic dose of 4000 mg of APAP is often exceeded, potentially causing acute or chronic liver failure, making abuse and subsequent tolerance of DXM-containing drugs potentially fatal.
An online essay first published in 1995 entitled "The DXM FAQ" described dextromethorphan’s potential for recreational use, and classified its effects into plateaus.
Owing to its recreational use and theft concerns, many retailers in the US have moved dextromethorphan-containing products behind the counter so that one must ask a pharmacist to receive them or be 18 years (19 in New Jersey, Nebraska, and Alabama, 21 in Mississippi) or older to purchase them. Some retailers also give out printed recommendations about the potential for abuse with the purchase of products containing dextromethorphan.
At high doses, dextromethorphan is classified as a dissociative general anesthetic and hallucinogen, similar to the controlled substances ketamine and phencyclidine (PCP). Also like those drugs, dextromethorphan is an NMDA receptor antagonist. Dextromethorphan generally does not produce withdrawal symptoms characteristic of physically addictive substances, but there have been cases of psychological addiction. Due to dextromethorphan's SSRI (selective serotonin re-uptake inhibitor)-like action, the sudden cessation of recreational dosing in tolerant individuals can result in mental and physical withdrawal symptoms similar to the withdrawal from SSRIs. These withdrawal effects can manifest as psychological effects, including depression, irritability, cravings, and as physical effects, including lethargy, body aches, and a sensation of unpleasant tingling, not unlike a mild "electric shock". 
Dextromethorphan, when consumed in low "recreational doses" (between 100 & 200 mg), is described as having a euphoric effect. With middle doses (about 400 mg, or 2.5 to 7.5 mg/kg), intense euphoria, vivid imagination, and closed-eye hallucinations may occur. With high doses (600 mg, or 7.5 mg/kg and over), profound alterations in consciousness have been noted, and users often report out-of-body experiences or temporary psychosis. Flanging (speeding up or slowing down) of sensory input is also a characteristic effect of recreational use.
There is also a marked difference between dextromethorphan hydrobromide, contained in most cough suppressant preparations, and dextromethorphan polistirex, contained in the brand name preparation Delsym. Polistirex is polymer that is bonded to the dextromethorphan that requires more time for the stomach to digest it as it requires that an ion exchange reaction take place prior to its dissolution into the blood. Because of this, dextromethorphan polistirex takes considerably longer to absorb, resulting in more gradual and longer lasting effects reminiscent of time release pills. As a cough suppressant, the polistirex version lasts up to 12 hours. This duration also holds true when used recreationally.
In 1981, a paper by Gosselin estimated that the lethal dose is between 50 and 500 mg/kg. Doses as high as 15–20 mg/kg are taken by some recreational users. It is suggested by a single case study that the antidote to dextromethorphan overdose is naloxone, administered intravenously.
A document entitled "The DXM FAQ," by William E. White, classified dextromethorphan's high-dose effects into four or five plateaus, each defined by a dosing range. The dosages are specified in ratios of milligrams (of the drug) per kilogram (of one's body mass). Doses are experimentally, not scientifically derived. According to the FAQ, the plateaus occur as follows:
Dextromethorphan has not been shown to cause vacuolization in animals, also known as Olney's lesions, despite early speculation that it may, due to similarities with Phencyclidine (PCP). In rats, oral administration of dextromethorphan did not cause vacuolization in laboratory tests. Oral administration of dextromethorphan repeatedly during adolescence, however, has been shown to impair learning in those rats during adulthood. The occurrence of Olney's lesions in humans, however, has not been proven or disproven. William E. White, author of the DXM FAQ, has compiled informal research from correspondence with dextromethorphan users suggesting that heavy abuse may result in various deficits corresponding to the brain areas affected by Olney's lesions; these include loss of episodic memory, decline in ability to learn, abnormalities in some aspects of visual processing, and deficits of abstract language comprehension.
A formal survey of dextromethorphan users showed that more than half of users reported experience of the following symptoms individually for the first week after dextromethorphan use: fatigue, apathy, flashbacks, and constipation. Over a quarter reported insomnia, nightmares, anhedonia, impaired memory, attention deficit and decreased libido. Rarer side effects included panic attacks, impaired learning, tremor, jaundice, urticaria (hives) and myalgia. Frequent and long-term usage at very high doses could possibly lead to toxic psychosis and other permanent psychological problems.
Erectile dysfunction and diminished libido can be a longer-term effect (years to decades) of many narcotic analgesics due to development of central hypogonadism; this appears especially common in individuals with significant melanin deficiencies, as the hormones tied to melanin production affect the absorption and conversion of these analgesics into progesterone. Additionally, the haplotypes of about 48% of the indigenous population of Great Britain aggravate the condition, as the E647 sequence underwent epigenetic degradation and became a pseudogene. The chance of vulnerability is doubled for males, as the critical sequence is located on the X chromosome.
Misuse of multi-symptom cold medications, rather than using a cough suppressant whose sole active ingredient is dextromethorphan, carries significant risk of fatality or serious illness. Multi-symptom cold medicines contain other active ingredients, such as paracetamol (acetaminophen), chlorpheniramine, and phenylephrine, any of which can cause permanent bodily damage such as kidney failure, or even death, if taken on the generally-accepted recreational dosing scale of dextromethorphan. Sorbitol, an artificial sweetener found in many cough syrups containing dextromethorphan, can also have negative side effects including diarrhea and nausea when taken at recreational dosages of dextromethorphan. Guaifenesin, an expectorant commonly accompanying dextromethorphan in cough preparations, can cause unpleasant symptoms including vomiting, nausea, and headache.
Combining dextromethorphan with other substances can compound risks. CNS stimulants such as amphetamine and/or cocaine can cause a dangerous rise in blood pressure and heart rate. CNS depressants such as ethanol (drinking alcohol) will have a combined depressant effect, which can cause a decreased respiratory rate. Combining dextromethorphan with other CYP2D6 substrates can cause both drugs to build to dangerous levels in the bloodstream.
Combining dextromethorphan with other serotonergic drugs could possibly cause serotonin toxicity, an excess of serotonergic activity in the central nervous system (CNS) and peripheral nervous system (PNS).
Dextromethorphan's hallucinogenic and dissociative effects can be attributed largely to dextrorphan (DXO), a metabolite produced when dextromethorphan is metabolized by the body. Both dextrorphan and dextromethorphan are NMDA receptor antagonists, like the dissociative hallucinogenic drugs ketamine and phencyclidine (PCP), although dextrorphan is more potent than its "parent molecule" dextromethorphan.
As with all NMDA receptor antagonists, dextrorphan and dextromethorphan inhibit the excitatory amino acid and neurotransmitter glutamate in the brain. This can effectively slow, or even shut down certain neural pathways, preventing areas of the brain from communicating with each other. This leaves the user feeling dissociated or disconnected, experienced as brain fog or derealization.
Dextromethorphan's euphoric effects have sometimes been attributed to an increase in dopamine levels, since such an increase generally correlates with pleasurable responses to drug, as is observed with some clinical antidepressants, as well as some recreational drugs. However, the effects of dextrorphan and dextromethorphan, and other NMDA receptor antagonists, on dopamine levels is a disputed subject. Studies show that the NMDA receptor antagonists ketamine and PCP do raise dopamine levels, although other studies show that another NMDA receptor antagonist dizocilpine has no effect on dopamine levels. Some findings even suggest that dextromethorphan can actually counter the dopamine-increasing effect caused by morphine. Due to these conflicting results, the actual effect of dextromethorphan on dopamine levels remain undetermined.
|The examples and perspective in this section may not represent a worldwide view of the subject. (December 2010)|
No legal distinction currently exists in the United States between medical and recreational use, sale, or purchase. Some states and store chains have implemented restrictions, such as requiring signatures for DXM sale, limiting quantities allowable for purchase, and requiring that purchasers be over the age of majority in their state.
The sale of dextromethorphan in its pure powder form may incur penalties, although no explicit law exists prohibiting its sale or possession, other than in the state of Illinois. There have been cases of individuals being sentenced to time in prison and other penalties for selling pure dextromethorphan in this form, because of the incidental violation of more general laws for the sale of legitimate drugs — such as resale of a medication without proper warning labels.
Dextromethorphan was excluded from the Controlled Substances Act (CSA) of 1970 and was specifically excluded from the Single Convention on Narcotic Drugs. Dextromethorphan is still excluded from the CSA (as of 2010); however, officials have warned that it could still be added if increased abuse warrants its scheduling. The motivation behind its exclusion from the CSA was that, under the CSA, all optical isomers of listed Schedule II opiates are automatically Schedule II substances. Since dextromethorphan is an optical isomer of the Schedule II opiate levomethorphan (but does not act like an opiate), an exemption was necessary to keep it a non-controlled substance. Because of its chemical similarity to levomethorphan, DXM could also be treated as a Schedule II drug under the Federal Analog Act.